Multiple sclerosis (MS) is a chronic and devastating autoimmune demyelinating disease of the central nervous system. With the increased understanding of the pathophysiology of this disease in the past two decades, many disease-modifying therapies that primarily target adaptive immunity have been shown to prevent exacerbations and new lesions in patients with relapsing-remitting MS. However, these therapies only have limited efficacy on the progression of disability. Increasing evidence has pointed to innate immunity, axonal damage and neuronal loss as important contributors to disease progression. Remyelination of denuded axons is considered an effective way to protect neurons from damage and to restore neuronal function. The identification of several key molecules and pathways controlling the differentiation of oligodendrocyte progenitor cells and myelination has yielded clues for the development of drug candidates that directly target remyelination and neuroprotection. The long-term efficacy of this strategy remains to be evaluated in clinical trials. Here, we provide an overview of current and emerging therapeutic concepts, with a focus on the opportunities and challenges for the remyelination approach to the treatment of MS.
Introduction
Multiple sclerosis (MS) mainly affects young adults, most being diagnosed between the ages of 20 and 50 years. Remyelination usually occurs during the early phase of the disease but eventually fails as it progresses, leaving chronic lesions largely demyelinated. Pathological studies have shown that abundant oligodendrocyte progenitor cells (oPCs) exist in the adult, and oPCs, either endogenous or transplanted, migrate to and re-populate demyelinated lesions. However, they cannot effectively remyelinate the denuded axons [1] [2] [3] . A non-permissive environment for oPC Yueting Zhang, et al. Promoting remyelination for the treatment of multiple sclerosis: opportunities and challenges 145 differentiation and myelination has been suggested to be the main cause for remyelination failure. This sustained demyelination, along with axonal damage and neurodegeneration, leads to the accumulation of neurological deficits, which are the main feature of the chronic progressive phase of the disease. While adaptive immunity accounts for the acute phase, increasing evidence indicates that innate immunity may be a driving force for disease progression [4] .
Marketed Drugs and Emerging Therapies
The advancement of our understanding of the pathophysiology of MS has led to the development of many diseasemodifying therapies in the past two decades. These treatments mainly target RRMS patients and have demonstrated reasonable efficacy in reducing the relapse rate and the formation of new lesions, but they are relatively ineffective in preventing the progression of disability. Pathologically, MS is a very heterogeneous disease. Lassman et al. have categorized it into four major types based on autopsies [5] ;
it is therefore not surprising that therapy against one type may not be effective against another.
So far, eight drugs have been approved for treating RRMS: three beta interferons (Betaferon, Rebif, and Avonex), glatiramer acetate (Copaxone), mitoxantrone (Novantrone), natalizumab (Tysabri), the first oral agent, fingolimod (Gilenya), and the newly-approved oral drug teriflunomide (Aubagio). An overview is presented in Table 1 .
These drugs can be classified into three categories based on their mechanisms of action: (1) immunomodulation, such as beta interferons and Copaxone, which are currently commonly used as first-line therapies, as they modestly reduce relapses and are generally well-tolerated; (2) general immunosuppression, such as by mitoxantrone and teriflunomide; and (3) blockade of the infiltration of immune cells into the CNS, such as natalizumab (anti-VLA4) and fingolimod (S1P receptor agonist). The evolution of current therapies reveals a trend from general immunomodulation and immunosuppression to more specific targeting with a better risk/benefit profile. Many new agents are still under development, but they all target the immune system. As shown in Table 2 , most of the developing assets are monoclonal antibodies with only a few oral drugs in the pipeline.
Given indeed, at least in preclinical research, it has been demonstrated that agents capable of promoting oPC differentiation promote remyelination in animal models of MS [6] [7] [8] .
In vitro and in vivo Models of OPC Differentiation and Myelination our understanding of the process of oPC differentiation and myelination has been greatly advanced using a number of increasingly sophisticated in vitro and in vivo tools.
The most widely used in vitro model is primary culture of oPCs, as isolated oligodendrocytes in culture follow a developmental program that is very similar to that in vivo [9] , suggesting that intrinsic regulation exists to instruct oPCs to differentiate into mature oligodendrocytes and produce process [10] . Slice cultures can, to some extent, maintain the 3D architecture of the cerebellar white and grey matter and provide a valuable ex vivo model to study demyelination/ remyelination. Although it is hard to target a single cell type in the slice, a potential way to overcome this is the addition 
Efficacy
All efficacies refer to comparison with placebo unless specified otherwise. Inj, injectable; ARR, annual relapse rate.
*, compared to beta interferon 1a (Rebif); #, in RRMS patients without highly-active disease. [11, 12] . The cuprizone model is another widely used toxin-based method that offers the ease of handling, as cuprizone is usually mixed with animal chow and ingested. All of these models rely on pathological examination of CNS myelin content to show demyelination, which can only be assessed after animal sacrifice, and all these models suffer from low throughput. An animal model with a far higher throughput is desirable for the purpose of drug screening. For this, ethidium bromide-induced demyelination of the developing zebrafish embryo fits the bill [13, 14] .
This model provides a pair of powerful in vivo readouts in the transgenic fish, i.e. mobility and myelin imaging. On the other hand, since the cuprizone model results in profound demyelination of the corpus callosum in mammals, in vivo functional readouts such as rotarod behavior and translatable imaging markers such as diffuse tensor imaging have been attempted [15] . in addition, recording the electric conductance along the white matter in acutely-isolated slices may be another functional readout. it is important to realize that these toxin-based demyelination models do not mimic 
Intrinsic Signals
it has long been appreciated that much of the regulation of oligodendrocyte differentiation is intrinsic in nature, with mechanisms like an internal "clock" limiting the number of cell divisions or cell cycle time in oPC cultures in the absence of neurons [16] . one important transcription factor is Olig2. The initial specification of the oligodendrocyte lineage is dependent on olig2 and this lineage is absent from olig2-null mice [17] . olig2 induces transcription factors that are required for the generation of mature, postmitotic oligodendrocytes, notably olig1, Sox-10, Nkx2.2, Nkx6.2, Ying
Yang 1, and ZFP488 [18] [19] [20] [21] [22] [23] . [24] [25] [26] .
Myelin Gene Regulatory Factor
MRF (also known as Gene Model 98) is a critical transcrip-tional regulator of oligodendrocyte maturation and CNS myelination. MRF is specifically expressed by postmitotic oligodendrocytes and promotes rapid oPC differentiation into myelin basic protein-positive and myelin oligodendrocyte glycoprotein-positive oligodendrocytes [24] . in mice lacking MRF in the oligodendrocyte lineage, the initial differentiation of oPCs into pre-myelinating oligodendrocytes is unaffected; however, these pre-myelinating oligodendrocytes fail to express the majority of myelin genes and the mice display severe neurological abnormalities [24] . Furthermore, MRF is reported to be required for the maintenance of myelin in mature oligodendrocytes. Ablation of MRF using an inducible conditional knockout strategy in myelinating cells causes delayed but severe CNS demyelination. These findings demonstrate an ongoing requirement for MRF in the maintenance of both mature oligodendrocyte identity and the myelin sheath [27] .
Zinc Finger Protein 191
Zfp191 is another transcription factor identified as being required for CNS myelination [25] . in the absence of Zfp191,
the oligodendrocyte lineage appears to stall at a much later stage than occurs in the absence of other factors such as olig1, Sox10 and MRF; relatively normal numbers of CC1-positive oligodendrocytes are generated and capable of contacting axons, but fail to fully myelinate them.
Retinoid X Receptor-gamma
RXRγ was recently identified as a factor regulating myelination in a microarray analysis of separate stages of spontaneous remyelination after focal demyelination in the rat CNS [28] . RXRγ is highly expressed in remyelinating lesions, suggesting that it may be important in lesion repair. This was further investigated by gain/loss-of-function studies in purified OPC and cerebellar slice cultures. Knockdown of RXRγ by RNA interference or RXR-specific antagonists severely inhibits oligodendrocyte differentiation in culture, while the RXR agonist 9-cis-retinoic acid promotes remyelination in demyelinated cerebellar slice cultures and in demyelinated aged rats [28] . However, given the pleiotropic roles of RXRγ and its diverse partners, a general RXRγ agonist may have significant side effects. Hence, the identification of those RXR partners that are responsible for the remyelination effect may provide a good intervention point for drug targeting.
G Protein-Coupled Receptor 17
GPR17 is a Gi-coupled receptor with expression restricted to the early differentiation stages of oligodendrocyte-lineage cells, and it is downregulated during the peak period of myelination and in adulthood [29] . Gpr17-knockout mice show early-onset oligodendrocyte myelination, while Gpr17 overexpression inhibits oligodendrocyte differentiation and maturation both in vivo and in vitro [26] . However, another study showed that treatment with the endogenous GPR17 ligand UDP-glucose promotes the differentiation of oPCs into mature myelin basic protein-positive oligodendrocytes [30] .
Follow-up studies further showed that GPR17 is restricted to NG2-and o4-positive oPCs and immature oligodendrocytes. Activation with natural ligands inhibits cAMP production and this inhibition is reversed by siRNA knockdown of GPR17. it was hypothesized that GPR17 keeps oPC in immature stages by inhibiting cAMP formation early in differentiation. When a critical stage of oPC differentiation is reached, GPR17 is downregulated to allow the reversal of cAMP to appropriate levels necessary for terminal maturation [31, 32] . These studies together suggest that GPR17 is an intrinsic timer that controls oPC maturation.
Notch
The involvement of Notch signaling in oPC differentiation in both development and pathological conditions has been extensively studied. The canonical pathway through Jagged-Notch binding promotes the specification of oligodendrocyte-lineage cells from neural precursor cells while inhibiting their further differentiation into mature oligodendrocytes [33, 34] . in MS, Jagged is re-expressed in astrocytes at the borders of active lesions [35] . Conditional ablation of Notch from olig1-positive oligodendroglial cells results in accelerated remyelination after LPC-induced focal demyelination in the corpus callosum [36] . An earlier study using 2',3'-cyclic nucleotide phosphodiesterase promoter (CNP)-cre-driven deletion failed to show any effect on the rate of remyelination [37] . This discrepancy of outcomes may be due to the promoter used to drive the deletion of Notch, since CNP is only expressed from premature oligodendrocytes onwards. Furthermore, the non-canonical ligand contactin enhances oligodendrocyte differentiation and initiates the wrapping of contactin-expressing cells [33] . Therefore, the role of Notch signaling in the regulation of myelination is more complicated than first anticipated.
Wnt Signaling
The importance of Wnt signaling in postnatal myelination an effector of the Wnt-β-catenin pathway, as one such factor [38] . Tcf4 is expressed specifically in oPCs and is down-regulated in maturing oligodendrocytes. Enforced expression of constitutive β-catenin leads to delayed differentiation of oPCs in development. Dissociation of Tcf4/ β-catenin through developmental down-regulation of Tcf4 itself, upregulation of the β-catenin antagonist adenomatous polyposis coli or competition for β-catenin binding by histone deacetylases or Groucho/Tle1, drives oligodendrocytes to differentiate and myelinate [39] . All these data sug- [40] . Together, these findings indicate that Axin2 is an important regulator of remyelination and that tankyrase could be a good drug target for myelination.
Extrinsic Signals for OPC Differentiation and Myelination
Several signals in the environment also regulate oPC differentiation and myelination; many are inhibitory, such as the secreted factors BMP4 and LiNGo expressed in neurons. it has been suggested that in MS, a prevailing nonpermissive environment due to high levels of several inhibitory environmental cues, hampers oPC differentiation and remyelination.
Bone Morphogenetic Protein 4
BMP4 belongs to the TGFβ family. It promotes astroglial lineage determination at the expense of oligodendrogliogenesis and inhibits the differentiation of oPCs [41, 42] . More recent studies showed that BMP4 is increased during demyelination. Besides, infusion of noggin, its natural antagonist, promotes oligodendrogenesis in the subventricular zone and increases the density of mature oligodendrocytes and remyelinated axons in the remyelinating corpus callosum [43, 44] . Thus, inhibition of endogenous BMP signaling during demyelination promotes mature oligodendrocyte regeneration and remyelination. The interactions among the BMP, Notch, and Wnt signaling pathways have been reported. BMP4 increases the levels of Wnt (Tbx3) and Notch target genes (Jag1, Hes1, Hes5, Hey1, and Hey2) [45] . BMP
and Wnt-β-catenin also upregulate ID2 [42, 46] , an inhibitory factor for oPC differentiation, thereby enhancing the crosstalk among signaling pathways that are known to inhibit myelination and repair.
LINGO-1
LiNGo-1 (leucine-rich repeat and ig domain containing NOGO receptor interacting protein-1) is a CNS-specific protein expressed on both neurons and oligodendroglial cells.
it forms a complex with the Nogo receptor and inhibits neurite outgrowth [47] . Blocking LiNGo-1 leads to axonal regeneration, increased neuronal survival and functional recovery in models of spinal cord injury both in vitro and in vivo [47] .
LINGO-1 was recently also identified as a negative regula-
tor of oPC differentiation. in complex with TrkA, it inhibits oPC differentiation during development. Attenuation of LiNGo-1 function in oPCs by siRNA, dominant-negative LiNGo-1, LiNGo-1-Fc or LiNGo knockout, invariably promotes oPC differentiation and myelination in vitro [48] [49] [50] [51] . Blockade of LiNGo-1 signaling promotes myelination in oPC-DRG co-cultures and LPC-treated cerebellar slice cultures [50, 52] .
injection of a LiNGo-1-blocking antibody leads to remyelination in the EAE and LPC focal injection models. in MS lesions, LiNGo-1 is expressed by reactive astrocytes, macrophages/microglia and neurons [53] . All these data support the suggestion that antagonizing LiNGo-1 provides a therapeutic approach that favors both neuroprotection and remyelination. indeed, an anti-LiNGo-1 antibody is undergoing phase i clinical trials for treating MS.
Cell Adhesion Molecules
Myelination requires precisely-controlled cell-cell interactions and several cell adhesion molecules have been reported to be involved in this process.
Neural cell adhesion molecule (NCAM) and L1 cell adhesion molecule (L1CAM) are both members of the immunoglobulin superfamily. They are involved in many aspects of nervous system development, including axonal outgrowth and fasciculation, neuronal migration and survival, and synapse formation [54] . Polysialic acid NCAM (PSA-150 NCAM) is a post-translationally-modified version of NCAM existing on both oligodendrocytes and axons [55] [56] [57] [58] . Removal of PSA from axons [59] and oligodendrocytes [60] is a prerequisite for the initiation of myelination during development. in MS, PSA-NCAM is re-expressed on denuded axons in the plaque, and this could act as an inhibitor of remyelination and participate in disease progression [61] .
L1CAM has also been reported to be involved in the initiation of myelin formation [62, 63] . it is downregulated on myelinated axons and re-expressed in regenerating axons after spinal cord injury [64, 65] . Exogenous L1CAM is beneficial in promoting axon growth and functional recovery after spinal cord injury [66] and optic nerve lesion [67] and is involved in the regenerative growth of Purkinje cell axons in vivo [68] .
These data suggest that L1CAM is capable of overcoming the anti-regeneration cues in adult CNS lesions.
in addition to the above pathways, other factors have also been reported to play a role in regulating oPC differentiation and myelination, such as the protein tyrosine phosphatases Dusp15/VHY and PTPRZ, transcription factor nuclear factor iA, teneurin 4, and sema 6A [69] [70] [71] [72] . As there are multiple players involved in different layers regulating oPC differentiation and myelination, the whole process is quite complicated and is far from being clearly worked out.
one therefore needs to consider several general criteria in selecting a good drug target to promote remyelination: first, the protein or the pathway is dysregulated in MS; second, the protein is a druggable target, e.g. transcription factors are usually not druggable; third, intervention on the target has minimal side-effects (e.g. the target is not expressed everywhere); and fourth, the drug, when successfully developed, must be able to enter the brain to promote remyelination. Targets that fit all these criteria are rather scarce, which illustrates the difficulty in developing new therapies for remyelination, let alone the other challenges discussed below.
Challenges
The forgoing discussion reviewed the exciting discover- [73] [74] [75] [76] . in addition, several groups have reported pervasive subpial or meningeal inflammatory cell aggregates akin to ectopic germinal centers in the vicinity of cortical lesions [76, 77] . Based on the anatomical proximity, it is plausible that inflammatory cells trafficking into the CNS through the choroid plexus may set up sites of chronic inflammation atop the cortex within the blood-brain barrier and contribute to grey-matter demyelination. This hypothesis remains to be tested in experimental systems, but if supported, would provide a rationale for therapies that target innate lymphoid tissue cells which are the initial seeds for these structures [78] . in addition to the traditional staining of brain sections, modern molecular techniques are being used to study the contents of the MS lesions. Despite concerns about how tissues are preserved for this purpose and the caveat that post-mortem tissues may reflect only the endgame rather the ongoing disease process, some limited initial transcriptomic and 2D-mass spectrometry proteomic profiling data have been reported [79] . A cursory examination of the data reveals an enrichment of proteins important for material transport, structural integrity and adhesion. But data-mining of this treasure trove with bioinformatic tools will no doubt yield new clues about the myelination and neurodegeneration process that may one day contribute to new therapeutic targets.
The demonstration of successful remyelination in MS
patients cannot be achieved without significant advances in [80] [81] [82] [83] . As these techniques become more standardized and gain wider use, they will greatly enhance our ability to read the progression of the myelination process in patients. in fact, some late-phase trials have included pilot studies on these readouts just to gain experience on the nuances. Moreover, the proposed anti-LiNGo proofof-concept trial will use some of these imaging parameters as early indications of myelination efficacy (Biogen idec public disclosure). Together with measurements of regional/ cortical atrophy and retinal nerve fiber layer thickness, it is conceivable that we will soon be able to have a full array of imaging readouts from which to choose to assess the efficacy of a potential therapy on myelination and neurorepair in patients with MS.
Conclusions and Future Directions
Despite great success in combating relapses over the past two decades, we are still on a long way from significantly halting and reversing the progression of disability in MS.
Finding the therapeutic approaches that provide for CNS repair remains a great challenge. our understanding of how myelination in the CNS is regulated has greatly advanced in the past decade. The combined use of genetics, transcriptome analysis, in vitro and in vivo models has revealed many ligands and transcription factors in the myelination process. These findings and tools provide the foundations for drug discovery. it is noteworthy that phenotypic screening remains an essential tool for drug discovery [84, 85] .
However, translating the knowledge of oligodendrocyte development and myelination into therapeutic approaches remains a major challenge. A lack of translation across species is one concern. in addition, whether the mechanism of remyelination in disease recapitulates that in development is also a big question. Encouragingly, however, many of the mechanisms thus far identified as controlling developmental myelination appear to operate for remyelination in animal models. Scientists from the bench to the bedside are now coming together to mount a concerted effort to translate research into effective CNS-protective and restorative therapies. The time is ripe for this critical mass to produce a breakthrough.
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